Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joerg Ermann

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Annals of the Rheumatic Diseases|November 6, 2019
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)Maxime Dougados, James Cheng-Chung Wei, Robert Landewé, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2026
Systematic Engineering of Intra-Articular Drug Release Profiles Reveals a Key Determinant of Disease-Modifying Efficacy in Post-Traumatic OsteoarthritisJingjing Gao, Nutan Bhingaradiya, Ziting Judy Xia, et al.
The American Journal of Gastroenterology|January 6, 2025
Prevalence and Risk Factors of Spondyloarthritis Symptoms in a US-Based Multicenter Cohort of Patients With Inflammatory Bowel DiseaseSimon J Hong, Rahul S Dalal, Kristine A Kuhn, et al.
Arthritis Care & Research|January 3, 2025
Frequency of Spondyloarthritis Symptoms Among US Patients With Inflammatory Bowel Disease: A Cross-Sectional Multi-Center StudyJoerg Ermann, Simon J Hong, Andrew Stahly, et al.
Science Translational Medicine|October 19, 2018
Mixed-effects association of single cells identifies an expanded effector CD4<sup>+</sup> T cell subset in rheumatoid arthritisChamith Y Fonseka, Deepak A Rao, Nikola C Teslovich, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|September 8, 2021
The potent and selective RIPK2 inhibitor BI 706039 improves intestinal inflammation in the TRUC mouse model of inflammatory bowel diseaseJoerg Ermann, Mederbek Matmusaev, Emma K Haley, et al.
Biorxiv : the Preprint Server for Biology|June 3, 2024
A Mechanically Resilient Soft Hydrogel Improves Drug Delivery for Treating Post-Traumatic Osteoarthritis in Physically Active JointsNitin Joshi, Jing Yan, Mickael Dang, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 31, 2025
A mechanically resilient soft hydrogel improves drug delivery for treating post-traumatic osteoarthritis in physically active jointsNitin Joshi, Jing Yan, Mickael Dang, et al.
Arthritis Care & Research|September 25, 2015
American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial SpondyloarthritisMichael M Ward, Atul Deodhar, Elie A Akl, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 25, 2015
American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial SpondyloarthritisMichael M Ward, Atul Deodhar, Elie A Akl, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Annals of the Rheumatic Diseases|November 6, 2019
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)Maxime Dougados, James Cheng-Chung Wei, Robert Landewé, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2026
Systematic Engineering of Intra-Articular Drug Release Profiles Reveals a Key Determinant of Disease-Modifying Efficacy in Post-Traumatic OsteoarthritisJingjing Gao, Nutan Bhingaradiya, Ziting Judy Xia, et al.
The American Journal of Gastroenterology|January 6, 2025
Prevalence and Risk Factors of Spondyloarthritis Symptoms in a US-Based Multicenter Cohort of Patients With Inflammatory Bowel DiseaseSimon J Hong, Rahul S Dalal, Kristine A Kuhn, et al.
Arthritis Care & Research|January 3, 2025
Frequency of Spondyloarthritis Symptoms Among US Patients With Inflammatory Bowel Disease: A Cross-Sectional Multi-Center StudyJoerg Ermann, Simon J Hong, Andrew Stahly, et al.
Science Translational Medicine|October 19, 2018
Mixed-effects association of single cells identifies an expanded effector CD4<sup>+</sup> T cell subset in rheumatoid arthritisChamith Y Fonseka, Deepak A Rao, Nikola C Teslovich, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|September 8, 2021
The potent and selective RIPK2 inhibitor BI 706039 improves intestinal inflammation in the TRUC mouse model of inflammatory bowel diseaseJoerg Ermann, Mederbek Matmusaev, Emma K Haley, et al.
Biorxiv : the Preprint Server for Biology|June 3, 2024
A Mechanically Resilient Soft Hydrogel Improves Drug Delivery for Treating Post-Traumatic Osteoarthritis in Physically Active JointsNitin Joshi, Jing Yan, Mickael Dang, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 31, 2025
A mechanically resilient soft hydrogel improves drug delivery for treating post-traumatic osteoarthritis in physically active jointsNitin Joshi, Jing Yan, Mickael Dang, et al.
Arthritis Care & Research|September 25, 2015
American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial SpondyloarthritisMichael M Ward, Atul Deodhar, Elie A Akl, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 25, 2015
American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial SpondyloarthritisMichael M Ward, Atul Deodhar, Elie A Akl, et al.
Pageof 8